ライフサイエンスコーパス: clofazimine

1 followed by 2 mo of rifampin, isoniazid, and clofazimine.

2 One-half of the mice also received daily clofazimine.

3 4 mug/ml), linezolid (0.25 to 2 mug/ml), and clofazimine (0.03 to 0.25 mug/ml).

4 These results suggest that clofazimine accumulates in macrophages by forming a memb

5 Furthermore, mice that received clofazimine after BCG vaccination exhibited significantl

6 g system specifically designed for detecting clofazimine aggregates.

7 formation, we synthesized a closely related clofazimine analog that does not precipitate under physi

8 Clofazimine and beta-lactams may have unrealized potenti

9 therapy with three antibiotics: rifampicin, clofazimine, and dapsone.

10 drug's red color, it is widely believed that clofazimine bioaccumulation results in skin pigmentation

11 ug, pyrazinamide (Z), and a repurposed drug, clofazimine (C), may assist treatment shortening of drug

12 hly using charcoal-containing agar to reduce clofazimine carryover.

13 Here, biocrystals of clofazimine (CFZ) that form in vivo within macrophages w

14 The mechanism of action of clofazimine (CFZ), an antimycobacterial drug with a long

15 ed after 3 and 5 mo in mice treated with the clofazimine-containing and standard regimens, respective

16 ained after 3 and 6 mo of treatment with the clofazimine-containing and standard regimens, respective

17 4 mo of rifampin and isoniazid, with a 4-mo clofazimine-containing regimen: 2 mo of daily rifampin,

18 Although observational studies suggest that clofazimine-containing regimens are highly active agains

19 The clofazimine contribution was substantial in these experi

20 Also unlike pure clofazimine crystals, CLDIs fragmented when heated, and

21 Unlike pure clofazimine crystals, isolated CLDIs placed in distilled

22 orm in subcellular spaces correspond to pure clofazimine crystals, macrophages of clofazimine-fed mic

23 Clofazimine deserves further study for the treatment of

24 Therefore, clofazimine enhances Tcm cell expansion, which in turn p

25 dications (amiodarone, chloroquine, suramin, clofazimine, etc.) may produce a drug-induced lipidosis

26 Upon prolonged treatment, clofazimine extensively bioaccumulates and precipitates

27 to pure clofazimine crystals, macrophages of clofazimine-fed mice were elicited with an intraperitone

28 daily rifampin, isoniazid, pyrazinamide, and clofazimine followed by 2 mo of rifampin, isoniazid, and

29 relapse rate was 7% among mice treated with clofazimine for 8 to 9 months.

30 We report 22 patients treated with clofazimine for chronic graft-versus-host disease (cGVHD

31 -resistant tuberculosis, the contribution of clofazimine for the treatment of this disease has never

32 se +/-SD, 1.0+/-0.5 log 10 cfu/mL of blood), clofazimine had the greatest bacteriostatic efficacy in

33 A key drug for the treatment of leprosy, clofazimine has recently been associated with highly eff

34 drug regimen with or without the addition of clofazimine in a mouse model of multidrug-resistant tube

35 Consistent with the low concentrations of clofazimine in the skin, these results suggest that clof

36 To test whether clofazimine-induced skin pigmentation is due to CLDI for

37 mine in the skin, these results suggest that clofazimine-induced skin pigmentation is not due to clof

38 The mechanism by which clofazimine induces a response is unknown, but might be

39 Clofazimine is a poorly-soluble but orally-bioavailable

40 Thus, clofazimine is a promising anti-TB drug with the potenti

41 Clofazimine is a weakly basic, Food and Drug Administrat

42 Thus, clofazimine is safe and has encouraging efficacy in cGVH

43 Clofazimine (Lamprene) is an antimycobacterial drug that

44 Consequently, we hypothesized that clofazimine may also shorten the duration of treatment f

45 Clofazimine may contribute to new short-course DR-tuberc

46 d bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB reg

47 of the ETC inhibitors bedaquiline, Q203 and clofazimine on the Mtb ETC, and the value of the ETC as

48 reated with the same antibiotic (ethambutol, clofazimine, or rifampin) that had been administered to

49 mine-induced skin pigmentation is not due to clofazimine precipitation and CLDI formation, but rather

50 r 5 months, whereas all mice treated without clofazimine remained heavily culture-positive for the en

51 .61 and 4.68 in mice treated with or without clofazimine, respectively (P < 0.001).

52 Increased ETC activity potentiates clofazimine's production of reactive oxygen species, cau

53 el preferentially expressed by Tem cells, by Clofazimine selectively expands Tcm cells during BCG vac

54 olony counts were significantly lower in the clofazimine-treated mice than in the mice receiving the

55 In clofazimine-treated mice, skin cryosections revealed no

56 No additive effect of clofazimine was observed after the first week of treatme

57 Mice treated with clofazimine were culture-negative after 5 months, wherea

58 fashion with either ethambutol, rifampin, or clofazimine, were tested by three conventional methods u

59 t 2- to 8-fold increases in MICs for BDQ and clofazimine, whereas one atpE mutant exhibited a 50-fold

60 Conversely, the antibiotic clofazimine, which increases ROS via an NADH-dependent r

61 MAC bacteremia received clarithromycin plus clofazimine, with or without ethambutol, in a prospectiv